Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, GIN, 38000 Grenoble, France.
Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, GIN, 38000 Grenoble, France.
Curr Opin Neurobiol. 2020 Aug;63:122-130. doi: 10.1016/j.conb.2020.04.001. Epub 2020 May 12.
Over the past twenty years there have been numerous advances in our understanding of Huntington's disease (HD) and other neurodegenerative proteopathies such as Alzheimer's disease and Parkinson's disease. In each case, disease-specific proteins are expressed and accumulate; what has been less clear is precisely what problems are caused by the accumulation. Recently we have begun to appreciate that increased protein levels or changes in the ratios of different isoforms affect the movement of molecules along the axon, thereby disrupting neuronal function. Huntingtin, the protein involved in HD, plays a special role in axonal transport, and very recent studies have found that its activity - and the movement of its cargoes - is altered not only in HD but in other neurological diseases. Here, we contextualize these studies and consider how modulating huntingtin activity could provide new avenues to therapy.
在过去的二十年中,我们对亨廷顿病(HD)和其他神经退行性蛋白病(如阿尔茨海默病和帕金森病)的理解有了许多进展。在每种情况下,都会表达和积累特定于疾病的蛋白质;但不太清楚的是,究竟是什么导致了积累。最近,我们开始意识到,蛋白质水平的增加或不同异构体比例的变化会影响分子沿轴突的运动,从而破坏神经元功能。亨廷顿蛋白参与 HD 的发生,在轴突运输中发挥特殊作用,最近的研究发现,它的活性及其 cargo 的运动不仅在 HD 中,而且在其他神经疾病中都发生了改变。在这里,我们将这些研究置于上下文中,并考虑调节亨廷顿蛋白活性如何为治疗提供新途径。